
Emergent BioSolutions (EBS) Stock Forecast & Price Target
Emergent BioSolutions (EBS) Analyst Ratings
Bulls say
Emergent BioSolutions is currently undervalued, as evidenced by its discounted cash flow valuation and potential for growth in its MCM product segment. Risks to this outlook include generic competition for its NARCAN Nasal Spray and failure to obtain government contracts. However, the company's restructuring plan and focus on identifying revenue-generating opportunities through internal R&D and in-licensing initiatives provide a potential path for future growth.
Bears say
Emergent BioSolutions is facing challenges in their product portfolio with the presence of generic competitors, leading to a decline in revenue and earnings. Additionally, the company's reliance on government contracts for a significant portion of their revenue poses a risk, as evidenced by the recent impairment of long-lived assets. These factors, along with the ongoing opioid crisis, contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Emergent BioSolutions and is not a guaranteed prediction by Public.com or investment advice.
Emergent BioSolutions (EBS) Analyst Forecast & Price Prediction
Start investing in Emergent BioSolutions (EBS)
Order type
Buy in
Order amount
Est. shares
0 shares